Cell Signaling Technology

Product Pathways - Development

BCL9 Antibody #15096

BCL-9   BCL9   Lymphoma   sc-79868  

No. Size Price
15096S 100 µl ( 10 western blots ) ¥3,250.00 现货查询 购买询价 防伪查询
15096 carrier free & custom formulation / quantityemail request
Applications Dilution Species-Reactivity Sensitivity MW (kDa) Isotype
W 1:1000 Human, Endogenous 149 Rabbit

Species cross-reactivity is determined by western blot.

Applications Key: W=Western Blotting,


Species predicted to react based on 100% sequence homology: Bovine, Horse,

Specificity / Sensitivity

BCL9 Antibody recognizes endogenous levels of total BCL9 protein. The antibody also cross-reacts with an unidentified protein of 21 kDa in some cell lines.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding His138 of human BCL9 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from various cell lines using BCL9 Antibody. KARPAS cell Line source: Dr Abraham Karpas at the University of Cambridge.


B-cell CLL/lymphoma 9 protein (BCL9) is a widely conserved adaptor protein that functions as a transcriptional co-activator in the canonical Wnt signaling pathway (1,2). BCL9 is a core component of a nuclear protein complex (BCL9, LEF/TCF, β-catenin and PYGO) that regulates the transcription of Wnt-dependent target genes (3). Research studies show that disrupting the interaction between BCL9 and β-catenin suppresses oncogenic Wnt signaling, suggesting a potential avenue for therapeutic intervention in Wnt-mediated cancers (4). BCL9 promotes association of PYGO with the tail of histone H3 that has been methylated at lysine 4 (H3K4me), suggesting a specific chromatin remodeling function for BCL9 in the Wnt signaling pathway (5). Research studies in colon epithelium and adenocarcinomas suggest that BCL9 is required to mediate Wnt-dependent stem cell behaviors, such as epithelial-mesenchymal transition (6). Crystallography studies revealed that BCL9 contains a β-catenin binding site that is distinct from the majority of known β-catenin binding partners, making it an attractive target for therapeutic drug development (7).

  1. Townsley, F.M. et al. (2004) Nat Cell Biol 6, 626-33.
  2. de la Roche, M. et al. (2008) BMC Cancer 8, 199.
  3. Katoh, M. and Katoh, M. (2007) Clin Cancer Res 13, 4042-5.
  4. Takada, K. et al. (2012) Sci Transl Med 4, 148ra117.
  5. Fiedler, M. et al. (2008) Mol Cell 30, 507-18.
  6. Deka, J. et al. (2010) Cancer Res 70, 6619-28.
  7. Sampietro, J. et al. (2006) Mol Cell 24, 293-300.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!


Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Tween is a registered trademark of ICI Americas, Inc.

Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.

用户评论 --- 共 0


我要参与评论 :